EUVIMEDEUVIMED entdecken
Crossref

Impact of a personalized antidepressant prescription using genetics, socio-demographic and clinical data in major depressive disorder patients: A clinical study

Bertrand Saudreau, Sena Ece Ilgın, Redwan Maatoug, Nourredine Haddadi, Antoinette Lemoine, Bruno Millet

Journal of Affective Disorders · 2026-08 · 407 · 121753

DOI: 10.1016/j.jad.2026.121753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-08. Verfasst von Bertrand Saudreau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne University, Child and Adolescent Psychiatry Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013, Paris, France. Electronic address: bertrand…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents, Precision Medicine, Decision Support Systems, Clinical. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Israel Innovation Authority, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Major depressive disorder (MDD) is common and disabling, and antidepressant selection often follows a trial-and-error process. Predictix is an artificial intelligence-based clinical decision support tool integrating genetic, socio-demographic, and clinical data to assist personalized prescribing. OBJECTIVE To evaluate feasibility, preliminary clinical outcomes, tolerability, and acceptability of Predictix-guided antidepressant selection. METHODS This single-center, open-label pilot study was conducted at Pitié-Salpêtrière Hospital (Paris) between August 2020 and July 2021. Thirty adults meeting DSM-5 criteria for MDD were enrolled. Treatment was initiated according to Predictix recommendations and assessed at weeks 4 and 8. The primary outcome was response (≥50% reduction in QIDS-SR-16). Secondary outcomes included PHQ-9 and CGI-I response, tolerability, and acceptability. Analyses were performed on study completers. RESULTS Twenty patients completed the study and 18 were included in the primary analysis. The primary response rate was 55.6% (95% CI: 33.7-75.4%). Secondary response rates were 61.1% (PHQ-9) and 72.2% (CGII). Clinical improvement (CGI-I ≤ 3) occurred in 94.4%. Mean treatment duration was 9.4 ± 2.3 weeks. Tolerability was favorable, with 66.7% showing FIBSER burden ≤2. Acceptability was generally positive, although the two-week genetic analysis delay was noted as a practical limitation. CONCLUSIONS Predictix-guided prescribing was feasible and showed response rates within reported clinical ranges. Larger randomized controlled trials are required to determine clinical added value over standard prescribing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAntidepressive AgentsPrecision MedicineDecision Support Systems, ClinicalHumansFemaleAdultMalePilot ProjectsMiddle AgedFeasibility StudiesTreatment OutcomeArtificial Intelligence

Stichwörter der Autor:innen

Artificial intelligence (AI) in psychiatryClinical decision support systems (CDSS)Major depressive disorder (MDD)Personalized antidepressant prescriptionPharmacogenomics

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Sorbonne University, Child and Adolescent Psychiatry Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013, Paris, France. Electronic address: bertrand.saudreau@aphp.fr.
  • Marmara University, Psychiatry Department, 34889, Istanbul, Turkey. Electronic address: sena.ilgin@marmara.edu.tr.
  • Sorbonne University, Institut du Cerveau, Adult Psychiatry Department, AP-HP, Hôpital Pitié-Salpêtrière, 75013, Paris, France.
  • Hôpital universitaire Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'Hôpital, 75651, Paris cedex 13, France.
  • Department of Oncogenetics, APHP, GH Paris-Sud, Hôpital Paul Brousse, Inserm UMR-S 1193, Université Paris-Saclay, 14 Avenue Paul Vaillant Couturier, 94800, Villejuif, France.
  • Sorbonne University, Institut du Cerveau, Adult Psychiatry Department, AP-HP, Hôpital Saint Antoine, 75012, Paris, France. Electronic address: b.millet@aphp.fr.

Förderung

  • Israel Innovation Authority
  • European Commission

Zitieren

APA

Saudreau, B., Ilgın, S. E., Maatoug, R., Haddadi, N., Lemoine, A., & Millet, B. (2026). Impact of a personalized antidepressant prescription using genetics, socio-demographic and clinical data in major depressive disorder patients: A clinical study. Journal of Affective Disorders, 407, 121753. https://doi.org/10.1016/j.jad.2026.121753

Vancouver

Saudreau B, Ilgın SE, Maatoug R, Haddadi N, Lemoine A, Millet B. Impact of a personalized antidepressant prescription using genetics, socio-demographic and clinical data in major depressive disorder patients: A clinical study. Journal of Affective Disorders. 2026;407:121753. doi:10.1016/j.jad.2026.121753

BibTeX
@article{Saudreau2026,
  author = {Saudreau, Bertrand and Ilgın, Sena Ece and Maatoug, Redwan and Haddadi, Nourredine and Lemoine, Antoinette and Millet, Bruno},
  title = {Impact of a personalized antidepressant prescription using genetics, socio-demographic and clinical data in major depressive disorder patients: A clinical study},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {407},
  pages = {121753},
  doi = {10.1016/j.jad.2026.121753}
}
Kostenlos starten →